IL277135A - Pd1 binding agent - Google Patents

Pd1 binding agent

Info

Publication number
IL277135A
IL277135A IL277135A IL27713520A IL277135A IL 277135 A IL277135 A IL 277135A IL 277135 A IL277135 A IL 277135A IL 27713520 A IL27713520 A IL 27713520A IL 277135 A IL277135 A IL 277135A
Authority
IL
Israel
Prior art keywords
binding agent
binding
agent
Prior art date
Application number
IL277135A
Other languages
English (en)
Hebrew (he)
Inventor
William James Jonathan Finlay
Original Assignee
William James Jonathan Finlay
Ultrahuman Nine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William James Jonathan Finlay, Ultrahuman Nine Ltd filed Critical William James Jonathan Finlay
Publication of IL277135A publication Critical patent/IL277135A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL277135A 2018-03-08 2020-09-03 Pd1 binding agent IL277135A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1803746.5A GB201803746D0 (en) 2018-03-08 2018-03-08 PD1 binding agents
GBGB1813405.6A GB201813405D0 (en) 2018-03-08 2018-08-16 PD1 binding agents
PCT/EP2019/055927 WO2019170898A1 (en) 2018-03-08 2019-03-08 Pd1 binding agents

Publications (1)

Publication Number Publication Date
IL277135A true IL277135A (en) 2020-10-29

Family

ID=61972796

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277135A IL277135A (en) 2018-03-08 2020-09-03 Pd1 binding agent

Country Status (10)

Country Link
US (2) US10858435B2 (enExample)
EP (1) EP3762419A1 (enExample)
JP (1) JP2021515541A (enExample)
CN (1) CN111819199A (enExample)
AU (1) AU2019229676A1 (enExample)
CA (1) CA3092174A1 (enExample)
GB (2) GB201803746D0 (enExample)
IL (1) IL277135A (enExample)
SG (1) SG11202008246VA (enExample)
WO (1) WO2019170898A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
WO2021076197A1 (en) * 2019-10-15 2021-04-22 Diverse Biotech, Inc. Conjugate molecules
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) * 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
MA43028B1 (fr) * 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents

Also Published As

Publication number Publication date
AU2019229676A1 (en) 2020-08-20
WO2019170898A1 (en) 2019-09-12
SG11202008246VA (en) 2020-09-29
US10858435B2 (en) 2020-12-08
GB201813405D0 (en) 2018-10-03
EP3762419A1 (en) 2021-01-13
CN111819199A (zh) 2020-10-23
GB201803746D0 (en) 2018-04-25
JP2021515541A (ja) 2021-06-24
US20210101981A1 (en) 2021-04-08
US20200332006A1 (en) 2020-10-22
CA3092174A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
IL272643A (en) Binders
GB201802201D0 (en) Binding agents
SG11202008246VA (en) Pd1 binding agents
IL277131A (en) PD1 binding factors
IL268288A (en) Binders
GB201810492D0 (en) Composition
GB201913756D0 (en) Contrast agent
GB201804434D0 (en) Composition
GB201820878D0 (en) Composition
GB201812145D0 (en) Composition
ZA202103582B (en) Dna-cutting agent
ZA202103578B (en) Dna-cutting agent
GB201818827D0 (en) Composition
GB201801596D0 (en) Composition
GB201815031D0 (en) Composition
GB201810024D0 (en) Composition
SG10201909375UA (en) Composition
PL3709812T3 (pl) Środek wiążący na bazie pszenicy
GB201819861D0 (en) Composition
GB201818567D0 (en) Composition
GB201815032D0 (en) Composition
GB201809123D0 (en) Composition
HK40039906A (en) Pd1 binding agents
GB201808570D0 (en) Binding agents
GB201802595D0 (en) Binding agents